{
    "title": "To enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding brand name drugs and generic drugs.",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Drug Competition Act of 2001''.\n\nSEC. 2. FINDINGS.\n\n    Congress finds that--\n            (1) prescription drug costs are increasing at an alarming \n        rate and are a major worry of senior citizens and American \n        families;\n            (2) there is a potential for drug companies owning patents \n        on brand-name drugs to enter in private financial deals with \n        generic drug companies in a manner that could tend to restrain \n        trade and greatly reduce competition and increase prescription \n        drug costs for American citizens; and\n            (3) enhancing competition between generic drug \n        manufacturers and brand name manufacturers can significantly \n        reduce prescription drug costs to American families.\n\nSEC. 3. PURPOSE.\n\n    The purposes of this Act are--\n            (1) to provide timely notice to the Department of Justice \n        and the Federal Trade Commission regarding agreements between \n        companies owning patents on brand name drugs and companies who \n        could manufacture generic or bioequivalent versions of such \n        brand name drugs; and\n            (2) by providing timely notice, to--\n                    (A) enhance the effectiveness and efficiency of the \n                enforcement of the antitrust laws of the United States; \n                and\n                    (B) deter pharmaceutical companies from engaging in \n                anticompetitive actions or actions that tend to \n                unfairly restrain trade.\n\nSEC. 4. DEFINITIONS.\n\n    In this Act:\n            (1) Agreement.--The term ``agreement'' means an agreement \n        under section 1 of the Sherman Act (15 U.S.C. 1) or section 5 \n        of the Federal Trade Commission Act (15 U.S.C. 45).\n            (2) Antitrust laws.-- The term ``antitrust laws'' has the \n        same meaning as in section 1 of the Clayton Act (15 U.S.C. 12), \n        except that such term includes section 5 of the Federal Trade \n        Commission Act (15 U.S.C. 45) to the extent that such section \n        applies to unfair methods of competition.\n            (3) ANDA.--The term ``ANDA'' means an Abbreviated New Drug \n        Application, as defined under section 505(j) of the Federal \n        Food, Drug and Cosmetic Act (21 U.S.C 355(j)).\n            (4) Brand name drug company.--The term ``brand name drug \n        company'' means a person engaged in the manufacture or \n        marketing of a drug approved under section 505(b) of the \n        Federal Food, Drug and Cosmetic Act (21 U.S.C. 355(b)).\n            (5) Commission.--The term ``Commission'' means the Federal \n        Trade Commission.\n            (6) FDA.--The term ``FDA'' means the United States Food and \n        Drug Administration.\n            (7) Generic drug.--The term ``generic drug'' is a product \n        that the Food and Drug Administration has approved under \n        section 505(j) of the Federal Food, Drug and Cosmetic Act (221 \n        U.S.C. 355(j)).\n            (8) Generic drug applicant.--The term ``generic drug \n        applicant'' means a person who has filed or received approval \n        for an ANDA under section 505(j) of the Federal Food, Drug and \n        Cosmetic Act (21 U.S.C. 355(j)).\n            (9) NDA.--The term ``NDA'' means a New Drug Application, as \n        defined under section 505(b) of the Federal Food, Drug and \n        Cosmetic Act (21 U.S.C. 355(b))\n\nSEC. 5. NOTIFICATION OF AGREEMENTS AFFECTING THE SALE OR MARKETING OF \n              GENERIC DRUGS.\n\n    A brand name drug manufacturer and a generic drug manufacturer that \nenter into an agreement--\n            (1) regarding the sale or manufacture of a generic drug \n        equivalent of a brand name drug that is manufactured by that \nbrand name manufacturer. and\n            (2) which agreement could have the effect of limiting the \n        research, development, manufacture, marketing or selling of a \n        generic drug product that could be approved for sale by the FDA \n        pursuant to an ANDA,\nshall both file with the Commission and the Attorney General a notice \nthat such an agreement has been entered into, the text of the \nagreement, an explanation of the purpose and scope of the agreement, \nand an explanation of whether the agreement could delay, restrain, \nlimit, or in any way interfere with the production, manufacture, or \nsale of the generic version of the drug in question.\n\nSEC. 6. FILING DEADLINES.\n\n    Any notice, agreement, or other material required to be filed under \nsection 5 shall be filed with the Attorney General and the Commission \nnot later than 10 business days after the date the agreement is \nexecuted.\n\nSEC. 7. ENFORCEMENT.\n\n    (a) Civil Fine.--Any person, or any officer, director, or partner \nthereof, who fails to comply with any provision of this Act shall be \nliable for a civil penalty of not more than $20,000 for each day during \nwhich such person is in violation of this Act. Such penalty may be \nrecovered in a civil action brought by the United States or brought by \nthe Commission in accordance with the procedures established in section \n16(a)(1) of the Federal Trade Commission Act (15 U.S.C. 56(a)).\n    (b) Compliance and Equitable Relief.--If any person, or any \nofficer, director, partner, agent, or employee thereof, fails to comply \nwith the notification requirement under section 5 of this Act, the \nUnited States district court, for the district in which such person \nofficer, director, partner, agent, or employee thereof resides or does \nbusiness, may order compliance and grant such other equitable relief as \nthe court in its discretion determines necessary or appropriate, upon \napplication of the Commission or the Assistant Attorney General.\n\nSEC. 8. RULEMAKING.\n\n    The Commission, with the concurrence of the Assistant Attorney \nGeneral and by rule in accordance with section 553 of title 5, United \nStates Code, consistent with the purposes of this Act--\n            (1) may require that the notice of an agreement described \n        in section 5 of this Act be in such form and contain such \n        documentary material and information relevant to the agreement \n        as is necessary and appropriate to enable the Commission and \n        the Assistant Attorney General to determine whether such \n        agreement may violate the antitrust laws;\n            (2) may define the terms used in this Act;\n            (3) may exempt classes of persons or agreements from the \n        requirements of this Act; and\n            (4) may prescribe such other rules as may be necessary and \n        appropriate to carry out the purposes of this Act.\n\nSEC. 9. EFFECTIVE DATES.\n\n    This Act shall take effect 90 days after the date of enactment of \nthis Act."
}